Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Drug Profile

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - Sanaria

Latest Information Update: 28 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; Sanaria; University of Tubingen
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Falciparum malaria

Most Recent Events

  • 28 Jan 2020 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Mali (IV, Injection)
  • 22 May 2019 National Institute of Allergy and Infectious Diseases plans a phase I/II trial for Falciparum malaria in Mali (NCT03952650)
  • 17 Apr 2019 Phase-I/II clinical trials in Falciparum malaria (Prevention, In volunteers) in Germany (IV) (EudraCT2018-004523-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top